Balance Sheet Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			After hours 23:06:40
29.40 ^USD	-10.48%		31.40	+6.80%

05-25	Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10:30 AM
05-18	Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference	CI

41800.JHAbPguU8--PegXHR3lfICsZjcdh8xdg6fbKn80VzVA.YBVcDHikpqjmOFWKKyNrbFIu3JdZ3nk6m7OyrYls9SUVOEFrYt-f3dYoSA

Published financial data: BEAM THERAPEUTICS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	51.84M	60.92M	378M	63.52M	140M
Total Revenues	51.84M	60.92M	378M	63.52M	140M
Cost of Goods Sold, Total	232M	312M	437M	368M	410M
Gross Profit	-180M	-251M	-59.67M	-304M	-270M
Selling General & Admin Expenses, Total	57.22M	87.8M	117M	112M	114M
R&D Expenses	-	-	-	-	-
Other Operating Expenses, Total	57.22M	87.8M	117M	112M	114M
Operating Income	-238M	-338M	-176M	-416M	-384M
Interest Expense, Total	-9K	-	-	-	-
Interest And Investment Income	-	15.3M	46.68M	49.09M	43.73M
Net Interest Expenses	-9K	15.3M	46.68M	49.09M	43.73M
Income (Loss) On Equity Invest.	-	-	-	-	255M
Other Non Operating Income (Expenses)	-1M	23.9M	7.5M	2.27M	700K
EBT, Excl. Unusual Items	-239M	-299M	-122M	-364M	-84.11M
Merger & Related Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	17.69M	20.2M	-18.59M	-14.09M	3.94M
In Process R&D Expenses	-155M	-	-	-	-
Other Unusual Items	5.15M	18.9M	9.74M	1.59M	180K
EBT, Incl. Unusual Items	-371M	-260M	-131M	-377M	-79.99M
Income Tax Expense	-	-	1.37M	39K	-
Earnings From Continuing Operations	-371M	-260M	-133M	-377M	-79.99M
Net Income to Company	-371M	-260M	-133M	-377M	-79.99M
Minority Interest	-	-	-	-	-
Net Income - (IS)	-371M	-260M	-133M	-377M	-79.99M
Preferred Dividend and Other Adjustments	-	-	-	-	-
Net Income to Common Incl Extra Items	-371M	-260M	-133M	-377M	-79.99M
Net Income to Common Excl. Extra Items	-371M	-260M	-133M	-377M	-79.99M
Per Share Items
Net EPS - Basic	-5.77	-3.72	-1.72	-4.58	-0.81
Basic EPS - Continuing Operations	-5.77	-3.72	-1.72	-4.58	-0.81
Basic Weighted Average Shares Outstanding	64.23M	70.02M	77.15M	82.31M	98.91M
Net EPS - Diluted	-5.77	-3.72	-1.72	-4.58	-0.81
Diluted EPS - Continuing Operations	-5.77	-3.72	-1.72	-4.58	-0.81
Diluted Weighted Average Shares Outstanding	64.23M	70.02M	77.15M	82.31M	98.91M
Normalized Basic EPS	-2.32	-2.67	-0.99	-2.77	-0.53
Normalized Diluted EPS	-2.32	-2.67	-0.99	-2.77	-0.53
Supplemental Items
EBITDA	-230M	-324M	-156M	-394M	-361M
EBITA	-238M	-338M	-176M	-416M	-384M
EBIT	-238M	-338M	-176M	-416M	-384M
EBITDAR	-209M	-301M	-120M	-357M	-329M
Effective Tax Rate - (Ratio)	-	-	-1.04	-0.01	-
Normalized Net Income	-149M	-187M	-76.44M	-228M	-52.57M
Interest on Long-Term Debt	-	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	57.22M	87.8M	117M	112M	114M
Research And Development Expense From Footnotes	387M	312M	437M	368M	424M
Net Rental Expense, Total	21.41M	22.89M	36.84M	36.94M	32.51M
Imputed Operating Lease Interest Expense	11.99K	-	-	-	-
Imputed Operating Lease Depreciation	21.4M	-	-	-	-
Stock-Based Comp., COGS (Total)	26.64M	52M	57.81M	73.52M	56.12M
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	16.93M	32.32M	40.84M	47.14M	38.12M
Total Stock-Based Compensation	43.57M	84.32M	98.65M	121M	94.24M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	560M	233M	436M	282M	295M
Short Term Investments	406M	845M	754M	569M	950M
Total Cash And Short Term Investments	966M	1.08B	1.19B	851M	1.25B
Accounts Receivable, Total	300M	-	-	-	-
Total Receivables	300M	-	-	-	-
Prepaid Expenses	7.36M	14.76M	21.17M	27.41M	23.48M
Total Current Assets	1.27B	1.09B	1.21B	878M	1.27B
Gross Property Plant And Equipment	203M	264M	288M	288M	299M
Accumulated Depreciation	-16.08M	-30.17M	-50.18M	-72.11M	-94.13M
Net Property Plant And Equipment	187M	234M	238M	216M	205M
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	14.47M	14.68M	10.86M	9.4M	7.31M
Total Assets	1.47B	1.34B	1.46B	1.1B	1.48B
Liabilities
Accounts Payable, Total	7.47M	9.03M	1.62M	3.87M	10.23M
Accrued Expenses, Total	56.87M	30.72M	35.05M	36.13M	49.64M
Current Portion of Leases	9.83M	12.23M	13.26M	13.47M	14.36M
Unearned Revenue Current, Total	86.27M	136M	68.71M	109M	6.66M
Other Current Liabilities	53M	35.64M	86.93M	19.74M	16.04M
Total Current Liabilities	213M	224M	206M	182M	96.94M
Long-Term Leases	138M	170M	160M	148M	140M
Unearned Revenue Non Current	262M	202M	110M	33.22M	-
Other Non Current Liabilities	34.16M	12.69M	3.02M	7.04M	6.12M
Total Liabilities	648M	608M	478M	370M	243M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	684K	712K	816K	836K	1.02M
Additional Paid In Capital	1.59B	1.79B	2.17B	2.3B	2.88B
Retained Earnings	-768M	-1.06B	-1.19B	-1.57B	-1.64B
Comprehensive Income and Other	-50K	-2.43M	604K	679K	1.11M
Total Common Equity	827M	733M	981M	734M	1.24B
Total Equity	827M	733M	981M	734M	1.24B
Total Liabilities And Equity	1.47B	1.34B	1.46B	1.1B	1.48B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	67.6M	70.7M	78.73M	81.11M	99.31M
ECS Total Common Shares Outstanding	67.26M	69.58M	78.71M	81.06M	99.21M
Book Value / Share	12.29	10.54	12.47	9.05	12.48
Tangible Book Value	827M	733M	981M	734M	1.24B
Tangible Book Value Per Share	12.29	10.54	12.47	9.05	12.48
Total Debt	148M	182M	173M	161M	154M
Net Debt	-818M	-896M	-1.02B	-689M	-1.09B
Debt Equivalent Oper. Leases	171M	183M	295M	296M	260M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	35.23M	54.79M	69.67M	79.79M	85.04M
Full Time Employees	341	507	436	483	511

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-371M	-260M	-133M	-377M	-79.99M
Depreciation & Amortization - CF	7.45M	14.15M	20.01M	21.92M	22.29M
Depreciation & Amortization, Total	7.45M	14.15M	20.01M	21.92M	22.29M
(Gain) Loss on Sale of Investments - (CF)	-17.76M	-29.61M	-11.15M	-8.67M	-275M
Asset Writedown & Restructuring Costs	155M	-	-	-	14.51M
(Income) Loss On Equity Investments - (CF)	-	25.5M	-	-	-
Stock-Based Compensation (CF)	43.57M	84.32M	98.65M	121M	94.24M
Other Operating Activities, Total	4.91M	-63.28M	-7.72M	5.8M	9.51M
Change In Accounts Receivable	-300M	300M	-146K	-	-
Change In Accounts Payable	818K	2.37M	-7.58M	1.81M	6.04M
Change in Unearned Revenues	348M	-35.92M	-160M	-36.52M	-135M
Change in Other Net Operating Assets	62.28M	-14.82M	50.83M	-75.51M	-1.64M
Cash from Operations	-66.27M	22.53M	-149M	-347M	-345M
Capital Expenditure	-46.81M	-48.95M	-33.73M	-8.95M	-14.95M
Cash Acquisitions	620K	-	-	-	-78K
Investment in Marketable and Equity Securities, Total	-248M	-412M	106M	194M	-106M
Cash from Investing	-294M	-461M	71.84M	185M	-121M
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-2.12M	-2.29M	-2.25M	-485K	-
Total Debt Repaid	-2.12M	-2.29M	-2.25M	-485K	-
Issuance of Common Stock	767M	114M	279M	8.22M	478M
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-8.82M	-188K	-631K	-	-
Cash from Financing	756M	112M	276M	7.74M	478M
Net Change in Cash	396M	-327M	199M	-155M	11.51M
Supplemental Items
Cash Interest Paid	567K	376K	160K	32K	-
Levered Free Cash Flow	-335M	138M	-50.84M	-157M	-220M
Unlevered Free Cash Flow	-335M	138M	-50.84M	-157M	-220M
Change In Net Working Capital	191M	-300M	25.46M	30.43M	82.1M
Net Debt Issued / Repaid	-2.12M	-2.29M	-2.25M	-485K	-

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-15.41	-15.02	-7.87	-20.26	-18.55
Return on Total Capital	-22.36	-22.39	-10.66	-25.35	-20.97
Return On Equity %	-69.13	-33.35	-15.46	-43.94	-8.11
Return on Common Equity	-69.13	-33.35	-15.46	-43.94	-8.11
Margin Analysis
Gross Profit Margin %	-347.75	-411.48	-15.8	-478.67	-193.12
SG&A Margin	110.37	144.13	30.93	175.58	81.45
EBITDA Margin %	-443.76	-532.39	-41.43	-619.73	-258.62
EBITA Margin %	-458.13	-555.61	-46.73	-654.25	-274.57
EBIT Margin %	-458.13	-555.61	-46.73	-654.25	-274.57
Income From Continuing Operations Margin %	-714.91	-427.08	-35.09	-593.13	-57.24
Net Income Margin %	-714.91	-427.08	-35.09	-593.13	-57.24
Net Avail. For Common Margin %	-714.91	-427.08	-35.09	-593.13	-57.24
Normalized Net Income Margin	-287.55	-307.04	-20.24	-358.36	-37.62
Levered Free Cash Flow Margin	-646.83	227.05	-13.46	-246.42	-157.65
Unlevered Free Cash Flow Margin	-646.82	227.05	-13.46	-246.42	-157.65
Asset Turnover
Asset Turnover	0.05	0.04	0.27	0.05	0.11
Fixed Assets Turnover	0.33	0.29	1.6	0.28	0.66
Short Term Liquidity
Current Ratio	5.96	4.89	5.89	4.82	13.09
Quick Ratio	5.93	4.82	5.79	4.67	12.85
Operating Cash Flow to Current Liabilities	-0.31	0.1	-0.73	-1.91	-3.56
Average Days Payable Outstanding	10.84	9.67	4.44	2.73	6.28
Long Term Solvency
Total Debt/Equity	17.86	24.82	17.65	22.01	12.45
Total Debt / Total Capital	15.15	19.88	15	18.04	11.07
LT Debt/Equity	16.67	23.15	16.3	20.17	11.29
Long-Term Debt / Total Capital	14.14	18.55	13.85	16.53	10.04
Total Liabilities / Total Assets	43.93	45.33	32.77	33.55	16.39
EBIT / Interest Expense	-26.39K	-	-	-	-
EBITDA / Interest Expense	-23.18K	-	-	-	-
(EBITDA - Capex) / Interest Expense	-28.38K	-	-	-	-
Total Debt / EBITDA	-0.71	-0.6	-1.45	-0.45	-0.47
Net Debt / EBITDA	3.92	2.97	8.5	1.93	3.32
Total Debt / (EBITDA - Capex)	-0.58	-0.52	-1.13	-0.44	-0.45
Net Debt / (EBITDA - Capex)	3.2	2.56	6.63	1.89	3.17
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	216K	17.51	520.01	-83.18	120.01
Gross Profit, 1 Yr. Growth %	74.78	39.04	-76.2	409.52	-11.24
EBITDA, 1 Yr. Growth %	79.7	40.98	-51.76	151.57	-8.19
EBITA, 1 Yr. Growth %	78.9	42.51	-47.86	135.47	-7.67
EBIT, 1 Yr. Growth %	78.9	42.51	-47.86	135.47	-7.67
Earnings From Cont. Operations, 1 Yr. Growth %	90.47	-29.8	-54.16	184.28	-78.77
Net Income, 1 Yr. Growth %	90.47	-29.8	-54.16	184.28	-78.77
Normalized Net Income, 1 Yr. Growth %	22.25	25.47	-62.34	197.77	-76.9
Diluted EPS Before Extra, 1 Yr. Growth %	37.69	-35.61	-58.4	166.28	-82.33
Net Property, Plant and Equip., 1 Yr. Growth %	49.14	25.22	1.57	-9.05	-5.13
Total Assets, 1 Yr. Growth %	226.44	-9	8.79	-24.38	34.19
Tangible Book Value, 1 Yr. Growth %	236.67	-11.28	33.79	-25.25	68.82
Common Equity, 1 Yr. Growth %	236.67	-11.28	33.79	-25.25	68.82
Cash From Operations, 1 Yr. Growth %	-30.78	-133.99	-762.29	132.75	-0.62
Capital Expenditures, 1 Yr. Growth %	186.18	4.57	-31.09	-73.48	67.07
Levered Free Cash Flow, 1 Yr. Growth %	2.55K	-141.25	-136.76	210.83	40.75
Unlevered Free Cash Flow, 1 Yr. Growth %	2.55K	-141.25	-136.76	210.83	40.75
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	5.27K	4.94K	169.92	2.11	-39.17
Gross Profit, 2 Yr. CAGR %	81.71	55.89	-42.47	10.13	112.66
EBITDA, 2 Yr. CAGR %	79.19	59.16	-17.53	10.17	51.98
EBITA, 2 Yr. CAGR %	77.77	59.67	-13.8	10.8	47.45
EBIT, 2 Yr. CAGR %	77.77	59.67	-13.8	10.8	47.45
Earnings From Cont. Operations, 2 Yr. CAGR %	117.53	15.63	-40.2	14.16	-22.31
Net Income, 2 Yr. CAGR %	117.53	15.63	-40.2	14.16	-22.31
Normalized Net Income, 2 Yr. CAGR %	74.51	23.85	-28.39	5.89	-17.07
Diluted EPS Before Extra, 2 Yr. CAGR %	-35.91	-5.84	-45.44	5.31	-31.38
Net Property, Plant and Equip., 2 Yr. CAGR %	107.93	36.66	12.78	-3.89	-7.11
Total Assets, 2 Yr. CAGR %	207.34	72.35	-0.5	-9.3	0.73
Tangible Book Value, 2 Yr. CAGR %	102.76	72.83	8.95	0	12.34
Common Equity, 2 Yr. CAGR %	102.76	72.83	8.95	0	12.34
Cash From Operations, 2 Yr. CAGR %	-4.07	-51.49	50.05	292.62	52.09
Capital Expenditures, 2 Yr. CAGR %	93.38	72.99	-15.11	-57.25	-33.44
Levered Free Cash Flow, 2 Yr. CAGR %	154.16	230.44	-61.06	6.38	109.17
Unlevered Free Cash Flow, 2 Yr. CAGR %	154.16	230.44	-61.06	6.38	109.17
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	1.4K	2.41K	7	31.88
Gross Profit, 3 Yr. CAGR %	74.6	66.2	-16.68	19.03	2.49
EBITDA, 3 Yr. CAGR %	72.15	65.42	6.92	19.61	3.67
EBITA, 3 Yr. CAGR %	73.16	65.14	9.95	20.5	4.27
EBIT, 3 Yr. CAGR %	73.16	65.14	9.95	20.5	4.27
Earnings From Cont. Operations, 3 Yr. CAGR %	46.98	49.21	-12.02	0.55	-34.84
Net Income, 3 Yr. CAGR %	47.6	49.21	-12.02	0.55	-34.84
Normalized Net Income, 3 Yr. CAGR %	54.35	56.34	-14.42	15.15	-36.26
Diluted EPS Before Extra, 3 Yr. CAGR %	-47.79	-35.81	-25.72	-7.41	-41.93
Net Property, Plant and Equip., 3 Yr. CAGR %	122.63	75.59	23.79	4.97	-4.3
Total Assets, 3 Yr. CAGR %	106.68	104.84	47.85	-9.2	3.35
Tangible Book Value, 3 Yr. CAGR %	91.67	53.93	58.69	-3.91	19.08
Common Equity, 3 Yr. CAGR %	91.67	53.93	58.69	-3.91	19.08
Cash From Operations, 3 Yr. CAGR %	48.35	-32.11	15.94	73.69	148.36
Capital Expenditures, 3 Yr. CAGR %	52.79	57.55	27.29	-42.4	-32.66
Levered Free Cash Flow, 3 Yr. CAGR %	171.62	38.64	58.92	-22.43	16.78
Unlevered Free Cash Flow, 3 Yr. CAGR %	171.62	38.64	58.92	-22.43	16.78
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	412.3	466.27
Gross Profit, 5 Yr. CAGR %	-	-	11.99	40.98	21.21
EBITDA, 5 Yr. CAGR %	-	106.76	28.25	40.6	23.07
EBITA, 5 Yr. CAGR %	-	108.47	31	40.78	23.65
EBIT, 5 Yr. CAGR %	-	108.47	31	40.78	23.65
Earnings From Cont. Operations, 5 Yr. CAGR %	-	97.18	2.57	36.91	-16.29
Net Income, 5 Yr. CAGR %	-	97.18	2.83	36.91	-16.29
Normalized Net Income, 5 Yr. CAGR %	-	102.78	13.52	35.98	-15.49
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-38.1	-46.86	-20.08	-28.04
Net Property, Plant and Equip., 5 Yr. CAGR %	-	270.58	69.61	37.98	10.35
Total Assets, 5 Yr. CAGR %	-	254.34	54.28	47.88	26.81
Tangible Book Value, 5 Yr. CAGR %	-	138.83	52.91	29.54	38.21
Common Equity, 5 Yr. CAGR %	-	138.83	52.91	29.54	38.21
Cash From Operations, 5 Yr. CAGR %	-	50.14	49.03	36.98	29.23
Capital Expenditures, 5 Yr. CAGR %	-	164.59	20.78	-6.5	-1.79
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	24.89	24.7	77.04
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	24.89	24.7	77.04